Cronos (CRON) Short term Debt (2021 - 2023)

Cronos' (CRON) quarterly Short term Debt came in at $375000.0 in Q1 2023, down 2.34% quarter-over-quarter from $384000.0 in Q4 2022.

Cronos (CRON) Short term Debt (2021 - 2023) Analysis & Trends

Cronos' Short term Debt history runs 3 years deep, the most recent figure standing at $375000.0 for Q1 2023.

  • On a quarterly basis, Short term Debt changed N/A year-over-year to $375000.0 in Q1 2023; TTM through Mar 2023 was $375000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $384000.0, down 11.32% from the prior year.
  • Short term Debt fell to $375000.0 in Q1 2023 per CRON's latest filing, from $384000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $433000.0 in Q4 2021 and bottomed at $375000.0 in Q1 2023.
  • The 3-year median for Short term Debt is $381500.0 (2022), against an average of $392750.0.
  • Biggest YoY gain for Short term Debt was 11.32% in 2022; the steepest drop was 11.32% in 2022.
  • Year by year, Short term Debt stood at $433000.0 in 2021, then dropped by 11.32% to $384000.0 in 2022, then slipped by 2.34% to $375000.0 in 2023.
  • Per Business Quant, the three latest CRON Short term Debt figures stand at $375000.0 (Q1 2023), $384000.0 (Q4 2022), and $379000.0 (Q3 2022).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Cronos 1.04 Bn 267.78 Mn 19.15 Mn

Historic Data

Download Data
DateValue
Mar 31, 2023 375,000.00
Dec 31, 2022 384,000.00
Sep 30, 2022 379,000.00
Dec 31, 2021 433,000.00